We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

November 26, 2021

Digital Mental Health: Status quo and future expectations

Commentary
&

This blog is the output from HealthXLs’ meeting series that explored DTx in the Mental Health space. Collective inputs from:

Jeff Weness (Head of Digital Opportunities and Business Intelligence at Otsuka), Krys Zaluski (Director, Frontier Business Office at Sumitomo Dainippon Pharma America), Francesca Wutkke (Chief Digital Officer at Almirall) , Azran Osman-Rani (CEO and Co-Founder at Naluri), Laura Stella Korcik (Founder & Managing Director at Vila Health UG), Aahuti Rai (Strategic Advisor | Healthcare Innovation at Four Points Consulting Ltd), Maria Arbiter (Behavioural Scientist at Ampersand Health), Eric Gastfriend (Founder and CEO at DynamiCare Health), Ivan Jurisic (Business Analyst for Digital Therapeutics at Roche), Arthur Bretonnet (Global Digital Innovation Immunology at UCB), Chandana Fitzgerald (GM & CMO at HealthXL), Meaghan Schedel (Digital Health Consultant at HealthXL) & Judit Faus (Community Manager at HealthXL) 


*All opinions are participants’ own and do not reflect the stance of their respective employers. 


Introduction:


Mental health is an area ripe for DTx given the lack of pharmacological treatments available and evidence showing that therapies are more effective than drugs for certain indications (e.g. anxiety). Poor accessibility to services, psychiatrist shortages, lack of objective tests and stigma, make mental health one of the most promising areas for digital health companies. This is especially pertinent now that the pandemic has boosted the demand for mental health services. In this series of 2 meetings we discussed the current state of DTx in mental health, what indications are best suited to such interventions, and the commercial opportunities that they present. 

 

Status Quo: Current solutions & Unmet Needs 

Mental health is a broad term that covers a vast number of conditions and diseases with different presentations and varying levels of extremity. It includes not only effective treatments for managing or alleviating the suffering from mental disorders but also strategies for preventing their onset. 


Most solutions in the digital mental health space address depression, anxiety, substance use disorder, and ADHD. However, tackling mental health comorbidities presents one of the biggest opportunities for DTx companies operating in this space. The bi-directional relationship between primary conditions and mental health impacts have spurred solutions aimed at mental health conditions that coexist with chronic diseases like cancer, psoriasis, and others. 


We have yet to see many companies create groundbreaking modes of action using digital products with most solutions simply offering a digitized version of Cognitive Behavioral Therapy (CBT). Beyond the R&D complexity of developing a more novel product, this is also likely due to the fact that it is more complicated to pursue FDA approval or payer reimbursement for a new mode of action vs. a digitized version of a well recognized and used therapy. 


A couple of areas that are purely digital and that are being explored, include the use of Virtual Reality (VR) or digital neuromodulation with clinician support and experience. However these treatments may be perceived as more expensive and the product delivery more complicated making adoption a challenge. Often these approaches need to be administered as part of a clinical visit rather than in lieu of. 



Unmet Need and Opportunities: 


Commercialisation models for DTx companies in mental health

There is no true one-route to market and the right approach seems to combine more than one path. While others exist, like the direct to hospital route used by Big Health in Scotland, we explored the following four distinct routes to market in this meeting: 


In the US in particular many mental health DTx solutions are offered D2C. An advantage of this is that a D2C model can help to build a customer base. With this model less clinical evidence is also needed, lowering the barrier to market entry. Companies that first take a D2C strategy can build evidence by collecting real world data and use this evidence to approach other commercialisation strategies. D2C solutions often gain more traction when they are physician recommended. 



For mental health DTx in particular, pharma partnerships may not yet be the best commercialisation model since the business model for pharma in this space is still very much in development. In the case of mental health in particular consideration is needed for the type of condition as well as how and if the DTx works together with a drug. These partnerships will be necessary for both DTx and pharma companies with success from this type of alliance likely to follow in the future. 



The payer and employer route can also be a successful commercialisation model for solutions that treat broad or large populations but perhaps less so for niche products. DTx that prevent mental health comorbidities in patients with chronic diseases might be interesting to payers and employers, as they mean cost savings. However, like the pharma route, long-term data and studies are highly desired and can be difficult for small start-ups to deliver on their own. Additionally, in the US there is a lack of payers consistency around where they want a DTx product to be i.e. medical benefits vs. pharmacy benefits. 



Some DTx in the space are also choosing partnerships with other digital health companies. For example, Silvercloud was acquired by Amwell and Ginger and Headspace merged. These types of partnerships can also be good options for mental health DTx. 


The right route to market for mental health DTx solutions will depend on the amount of evidence they have at the outset, what their long-term goals are, the condition they target, and also where they are geographically located. Location being a key factor particularly for the employer route which can be a great option in the US, but one that has not seen the same success in the EU. The EU is less familiar with a pay per service model and through programs like the DiGA in Germany, their regulatory and reimbursement paths are starting to be forged. 

Adoption and last-mile delivery challenges

Something which can and will affect adoption is the reality that with mental disorders people respond to treatments differently and there is a blurring of symptoms between one type of mental disorder vs. another. Typically if one type of therapy is not working for a patient, a psychiatrist may add another therapy to a patients’ treatment. However, many DTx solutions only offer one type of therapy which can limit adoption. Whilst each mental disorder may have its own clinical protocol in terms of diagnosis and treatment, there are synergies across them and so the more that approaches to mental health / mental disorder treatment can be 'aggregated', the higher the likelihood of success when it comes to DTx adoption.


Also important is more innovation from DTx manufacturers. DTx development needs to show that it can be more than the delivery of already proven treatments via software and that beyond this, DTx can offer a means to measure aspects of patient biology and behaviour in ways that were not previously possible. Particularly in mental health, this objective data collection will in turn allow better diagnosis and allow clinicians to adjust care as necessary. What may eventually be possible is the discovery of complex relationships between new forms of data and mental health conditions - i.e. being able to quantify complex concepts such as mood swings or binge eating that might underlie worsening mental health conditions. Therefore, educating clinicians on the power of the underlying data set that builds with DTx could motivate them beyond just seeing DTx as a software driven delivery of existing therapies.


Integration into HCPs systems and workflows can also help to facilitate prescriptions. Systems that rate different solutions like Orcha and the NHS library could make it easier for HCPs to prescribe these products. They make providers aware of the products and help them to assess their quality. They can also help them to sift through a crowded and noisy market of solutions claiming to be digital therapeutics. While these platforms can be beneficial, there are currently a number of them out there with inconsistencies in how solutions are identified. This can lead to discrepancies and make things more confusing and complicated for providers. 


This is where an increase in physician education will be critical. Better tools are needed to help show the value of DTx in mental health in order to increase adoption. Patient associations and/or digital KOLs can also help raise HCP awareness about mental health solutions and how they can enhance the diagnosis and treatment of mental health conditions. 


We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sprint: DTx last mile delivery: HCPs and Patient adoption (Part 2)

3rd February @ 10:45AM EDT

Are you struggling getting HCPs and/or patients to adopt your DTx products? Keep reading, this sprint is for you! Places are limited so apply now to join the second session of this series and discuss with other senior leaders, DTx last mile delivery.

Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: The Regulation of SaMD in the US

14th February @ 10:45AM EDT

Join us in this US-focused Masterclass led by Clay Anselmo and Bernhard Kappe, As they walk us through the regulation of SaMD in the US. Apply now to secure your place.

Featuring
Bernhard Kappe
Bernhard Kappe
Founder & CEO, Orthogonal
Clay Anselmo
Clay Anselmo
VP Quality Assurance and Regulatory Affairs, ENvizion
Featuring
Bernhard Kappe
Bernhard Kappe
Founder & CEO, Orthogonal
Clay Anselmo
Clay Anselmo
VP Quality Assurance and Regulatory Affairs, ENvizion
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx - Pharma partnerships

15th February @ 10:45AM EDT

Join us as we deep dive into DTx-Pharma partnerships, with a focus on how to monetize DTx within the traditional pharmaceutical business model. Apply now to connect with peers and hear from thought leaders in this space.

Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Mansa Shroff
Mansa Shroff
Head of Partnerships at WKD.SMRT
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Mansa Shroff
Mansa Shroff
Head of Partnerships at WKD.SMRT
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Webinar: DTx commercialisation models - Pharma Partnerships & D2C route

17th February @ 10:00AM EDT

Last month, we did a deep dive on the Employer route to market for DTx products. Join us this month as we look into other potential go-to-market strategies for Digital Therapeutics. Apply now to hear valuable insights from thought leaders in this space.

Featuring
Pierre Leurent
Pierre Leurent
CEO, Voluntis
Mette Dyhrberg
Mette Dyhrberg
Founder & CEO, Mymee
Featuring
Pierre Leurent
Pierre Leurent
CEO, Voluntis
Mette Dyhrberg
Mette Dyhrberg
Founder & CEO, Mymee

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation

Masterclass: Clinical Trials Design for Digital Health products

31st January @ 10:45AM EDT

Join us in this Masterclass led by Click Therapeutics, as we discuss Clinical Trials Design for Digital Health Products. Our Masterclass sessions are the perfect opportunity to hear from thought leaders in the space and share your own thoughts and experiences.

Featuring
Shaheen Lakhan
Shaheen Lakhan
Chief Medical Officer , Click Therapeutics
Featuring
Shaheen Lakhan
Shaheen Lakhan
Chief Medical Officer , Click Therapeutics
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation

Digital tech for Trial Recruitment and Retention

2nd February @ 10:45AM EDT

Join our Digital Health Meeting led by Laura Gunn from Pharmstars as we discuss digital tech for Trial Recruitment and Retention. This is the perfect opportunity to connect with peers and meet new people working in this space.

Featuring
Laura Gunn
Laura Gunn
Managing Director at PharmStars
George Platings
George Platings
Market Development Specialist at uMotif
Featuring
Laura Gunn
Laura Gunn
Managing Director at PharmStars
George Platings
George Platings
Market Development Specialist at uMotif
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sprint: DTx last mile delivery: HCPs and Patient adoption (Part 2)

3rd February @ 10:45AM EDT

Are you struggling getting HCPs and/or patients to adopt your DTx products? Keep reading, this sprint is for you! Places are limited so apply now to join the second session of this series and discuss with other senior leaders, DTx last mile delivery.

Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Featuring
Katie Archer
Katie Archer
Director, Health & Welfare Benefits Design, Planning and Analysis at The Hartford
Shrawan Patel
Shrawan Patel
Founder & MD, Strategy Health
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery

Digital Health Solutions with the greatest impact in cancer patients' lives

8th February @ 10:45AM EDT

How can Digital Health improve cancer patients’ lives? Are you working in this industry? Keep reading, this meeting is for you. Join us as we discuss current Digital Health products in oncology and the unmet/gaps need to be addressed.

Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd
Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Aahuti Rai
Aahuti Rai
Strategic Advisor, Healthcare Innovation at Four Points Consulting Ltd

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.